Intas Pharma files DRHP with SEBI; ChrysCapital eyes 13-14x part-exit

Premium

Ahmedabad-based Intas Pharmaceuticals Ltd has filed draft red-herring prospectus (DRHP) with the market regulator for an issue which will see ChrysCapital part-exit with over 13-14x returns, said sources familiar with the development. ChrysCapital has invested in Intas through two of its funds on seperate occasions, first in 2006 and then ......